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Background: A low vitamin D status has been put forward as a potential risk factor for the development of inflammatory bowel disease (IBD). 
This study investigated the association between prediagnostic circulating vitamin D concentrations and dietary intakes of vitamin D, and the risk 
of Crohn’s disease (CD) and ulcerative colitis (UC). 
Methods: Among 359,728 participants of the European Prospective Investigation into Cancer and Nutrition cohort, individuals who developed 
CD or UC after enrollment were identified. Each case was matched with2 controls by center, gender, age, date of recruitment, and follow-up 
time. At cohort entry, blood samples were collected and dietary vitamin D intakes were obtained from validated food frequency questionnaires. 
Serum 25-hydroxyvitamin D levels were measured using liquid chromatography-tandem mass spectrometry. Conditional logistic regression was 
performed to determine the odds of CD and UC. 
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Results: Seventy-two participants developed CD and 169 participants developed UC after a median follow-up of 4.7 and 4.1 years, respectively. 
Compared with the lowest quartile, no associations with the 3 higher quartiles of vitamin D concentrations were observed for CD (p 
trend 
= 0.34) or 
UC (p 
trend 
= 0.66). Similarly, no associations were detected when serum vitamin D levels were analyzed as a continuous variable. Dietary vitamin 
D intakes were not associated with CD (p 
trend 
= 0.39) or UC (p 
trend 
= 0.83). 
Conclusions: Vitamin D status was not associated with the development of CD or UC. This does not suggest a major role for vitamin D deficiency 
in the etiology of IBD, although larger studies are needed to confirm these findings. 
Key Words: vitamin D, Crohn’s disease, ulcerative colitis, inflammatory bowel disease, etiology 
 
INTRODUCTION 
The rising incidence and geographical variability of 
Crohn’s disease (CD) and ulcerative colitis (UC) suggest that 
environmental factors are involved in the etiology of these 
inflammatory bowel diseases (IBDs).1, 2 The role of  vitamin   
D in the pathogenesis of IBD has received increasing interest 
after the observation that vitamin D receptors (VDRs) are 
widely expressed throughout the body and that several tissues 
and cells, including immune cells, synthesize the active form 
of  vitamin  D,  1,25-dihydroxyvitamin  D  (1,25(OH)
2
D), from 
the primary circulating form, 25-hydroxyvitamin D (25(OH) 
D).3 Apart from well-established effects on calcium homeosta- 
sis and bone metabolism, binding of 1,25(OH)
2
D to the VDR 
may result in anti-inflammatory effects by modulation of both 
innate and adaptive immunity.4 
A low vitamin D status has been proposed as a poten- 
tial risk factor for the development of IBD based on different 
lines of evidence.4 In experimental animal models, vitamin D 
or VDR deficient mice develop more pronounced intestinal 
inflammation, whereas supplementation of 1,25(OH)
2
D sup- 
presses colitis.4–7 Notably, genetic polymorphisms in the VDR 
have been implicated in susceptibility to IBD in humans.8, 9 
Experimental studies indicate that  vitamin  D  plays  a  part 
in preserving the integrity of the intestinal mucosal bar- 
rier.10, 11 Furthermore, observational  studies  show  that  IBD 
is more common at higher latitudes,12, 13 where individuals 
have a lower exposure to ultraviolet B radiation from sun- 
light, the main  determinant  of vitamin  D  status.  Vitamin 
D deficiency is frequently observed in patients with estab- 
lished CD and UC, but this may be a  consequence rather  
than a cause of the  disease.  Data  on  prediagnostic vitamin 
D levels are scant.14 To date, a single  prospective  cohort 
study conducted in women from the United States reported  
an association between higher vitamin D status and lower 
risk of  incident CD,  and  to  a  lesser extent UC.15  However, 
a limitation of this study was that  these results were  based 
on predicted and not measured circulating 25(OH)D levels, 
whereas previous studies report that even extensive predic- 
tion models may only explain a limited fraction of 25(OH)D 
variability.16–18 Prospective studies using  accurate  measures 
of vitamin D status including from  European  populations 
are not available. 
The aim of this study was to investigate the association 
between prediagnostic circulating vitamin D concentrations 
measured from serum and dietary intakes of vitamin D, and 
the risk of CD and UC in a nested case-control study within the 
European Prospective Investigation into Cancer and Nutrition 
(EPIC) cohort. We hypothesized that a high vitamin D status 
decreases the risk of developing IBD. 
 
MATERIALS AND METHODS 
Study Population and Data Collection 
The EPIC study is a large, multicenter cohort inves- 
tigation initiated to examine the relationship between  life- 
style and environmental factors and the incidence of cancer 
and other chronic diseases. The design and methods of the 
EPIC project have been described elsewhere in detail.19, 20 The 
cohort used for the present study includes 359,728 men and 
women aged 20 to 80 years enrolled between 1992 and 2000 
from 12 centers in Denmark, France, Germany, Greece, Italy, 
the Netherlands, and the United Kingdom. Participants were 
recruited from the general population in all  centers,  apart 
from France (female school workers in a nationwide health 
insurance program), Florence and Utrecht (women in a breast 
cancer screening program), Ragusa (mainly blood  donors), 
and Oxford (vegetarians, vegans, and other health-conscious 
individuals). At enrollment, participants completed lifestyle 
and dietary questionnaires and anthropometric data were col- 
lected. In addition, blood samples were taken at cohort entry 
from most participants before diagnosis. Until further analy- 
ses, blood samples were stored at the International Agency for 
Research on Cancer (Lyon, France) in -196°C liquid nitrogen 
for all countries except Denmark (-150°C, nitrogen vapor). 
Participants’ habitual diet over the preceding 12 months before 
recruitment was assessed by validated country-specific food 
frequency questionnaires. National food composition tables 
were used to calculate daily intakes of total energy (in kcal), 
dietary vitamin D (in μg), and other nutrients. Information on 
supplement use was not available for all participants and was 
therefore not included. 
 
Follow-up and Identification of Cases and 
Controls 
Participants were followed-up from recruitment until 
at least May 2004, and in some centers were followed-up to 
September 2011. Individuals who developed CD or UC were 
 
 
  
 
 
identified by follow-up questionnaires, population-based dis- 
ease registries, hospital admission records, pathology databases, 
health insurance registries, or a combination of these meth- 
ods.21 Physicians in each center reviewed the medical records 
of potential cases to confirm the diagnoses and to obtain infor- 
mation on disease extent according to a standard protocol con- 
sistent across centers. Individuals with prevalent CD or UC 
at enrollment and individuals who developed microscopic or 
indeterminate colitis were excluded. In this nested case-control 
study, each case was matched with 2 randomly selected controls 
by center, gender, age at recruitment (±6 months), and date of 
recruitment (±3 months). Incidence density sampling was used 
to establish a similar follow-up time for cases and controls. 
Only cases (and their controls) with available serum samples 
were included in the present study. 
 
Laboratory Analysis 
The reliability of measuring biomarkers in serum sam- 
ples collected from the EPIC cohort, including vitamin D, has 
been investigated previously.22 Serum samples were analyzed 
for 25(OH)D and parathyroid hormone (PTH) concentrations. 
Levels of 25(OH)D were quantified for all cases and controls 
using liquid chromatography-tandem mass spectrometry (LC- 
MS/MS). This method was calibrated to the United States 
National Institute of Standards and Technology. Day-to-day 
imprecision was 7%, 5%, and 4.3% at 15 nmol/L, 49 nmol/L, 
and 87 nmol/L, respectively. Within-run imprecision (n = 10) 
was 3.8%, 3.5%, and 1.7% for these concentrations. PTH levels 
were measured by an electrochemiluminescence immunoassay 
on the Modular E411 (intact PTH, Roche Diagnostics GmbH, 
Mannheim, Germany). The lower limit of detection was 0.60 
pmol/L and the intraassay variation was less than 4.5% at 3.5 to 
112 pmol/L (reference interval 1 to 7 pmol/L (normal calcium)). 
All laboratory analyses were performed at the Department of 
Clinical Chemistry and Hematology at the University Medical 
Center Utrecht (Utrecht, the Netherlands) in May and June 
2016. Laboratory technicians were blinded to the case-control 
status of participants. 
 
Statistical Analysis 
Pearson’s correlation coefficient was used to determine 
the relationship between PTH levels and dietary vitamin D 
intakes and 25(OH)D levels. Conditional logistic regression 
models were computed to assess the association between serum 
25(OH)D concentrations and dietary vitamin D intakes and 
the risk of CD and UC by estimating odds ratios (ORs) and 
95% confidence intervals (CIs). Levels of 25(OH)D and diet- 
ary intakes of vitamin D were introduced in models as quar- 
tiles based on the distribution of the matched controls. For 
circulating 25(OH)D concentrations, analyses also were per- 
formed using serum levels as a continuous variable (increment 
10 nmol/L) and as a categorical variable based on predefined 
cutoffs of proposed levels of vitamin D deficiency (less than 
50 nmol/L), insufficiency (50 to less than 75 nmol/L), and suf- 
ficiency (equal or greater than 75 nmol/L).3 Restricted cubic 
spline analyses were performed to evaluate the possibility of a 
nonlinear association between 25(OH)D levels and the risk of 
IBD. The likelihood ratio test was used to compare the model 
with only the linear term to the model with the linear term and 
the cubic spline terms (5 knots).23 The p-value of this test was 
0.71 for CD and 0.82 for UC, implying no indications of non- 
linearity. Therefore, 25(OH)D concentrations were analyzed as 
a linear term in the analyses with 25(OH)D as a continuous 
variable. To test for trends across quartiles and categories, trend 
variables were assigned the median values for these groups. In 
multivariable models, analyses were adjusted for smoking sta- 
tus (categorized into never smoker, former smoker, and current 
smoker) since smoking has been consistently associated with 
CD and UC.24 Other potential confounders that reportedly  
were found to be associated25, 26 or not to be associated27–29   
with IBD, including PTH, linoleic acid, docosahexaenoic acid, 
body mass index, physical activity, alcohol intake, total dairy 
products, and dietary calcium intake, were examined but not 
included in the multivariable models as these factors did not 
significantly alter the associations. Two analyses were per- 
formed to correct for the possible influence of season or month 
of blood draw on 25(OH)D levels. First, additional adjustment 
for season of recruitment (winter, spring, summer, or autumn) 
was performed. Second, 25(OH)D levels were standardized for 
all participants by deriving residuals from a linear regression 
model fitted to 25(OH)D concentrations by month of recruit- 
ment. The standardized values were then analyzed as a con- 
tinuous variable in conditional logistic regression models as 
described above. The results were subsequently compared with 
those of the nonstandardized 25(OH)D levels.30 In a sensitiv- 
ity analysis, the analyses were repeated excluding cases diag- 
nosed less than 18 months after enrollment to minimize the 
risk of reverse causation. Two-sided p-values below 0.05 were 
deemed to indicate statistical significance. Statistical analyses 
were performed using SPSS version 21 (IBM Corp., Armonk, 
New York, United States) and RStudio version 3.2.2 (RStudio, 
Inc., Boston, Massachusetts, United States). GraphPad Prism 
version 6.02 (GraphPad Software, La Jolla, California, United 
States) was used for drawing figures. 
 
Ethical Considerations 
This study was approved by the International Agency for 
Research on Cancer Ethics Committee and the relevant ethics 
committees of participating EPIC centers. 
 
RESULTS 
In total, 72 participants with incident CD (median age 
at diagnosis 55.7 years, 77.8% female) and 169 participants 
with incident UC (median age at diagnosis 57.0 years, 48.5% 
female) were identified (Table 1). The median time between 
enrollment and diagnosis was 4.7 years (range 0.1–14.3 years) 
 
  
 
 
 
TABLE 1: Characteristics of Crohn’s Disease and Ulcerative Cases and their Controls 
 
CD Cases (n = 72) CD Controls (n = 144) UC Cases (n = 169) 
 
 
UC Controls 
(n = 338) 
Female, n (%) 56 (77.8) 112 (77.8) 82 (48.5) 164 (48.5) 
Age (years) at recruitment, median (IQR) 49.1 (41.3–60.7) 48.8 (41.6–59.3) 51.6 (46.1–57.9) 51.6 (46.1–57.5) 
Age (years) at diagnosis, median (IQR) 55.7 (47.1–63.3) - 57.0 (51.2–62.3) - 
Distribution of CD, n (%)  - - - 
L1, ileal 24 (33.3) - - - 
L2, colonic 25 (34.7) - - - 
L3, ileocolonic 18 (25.0) - - - 
L4, upper gastrointestinal disease 3 (4.2) - - - 
Unknown 4 (5.6)  
Distribution of UC, n (%) - - - 
E1, ulcerative proctitis - - 36 (21.3) - 
E2, left-sided colitis - - 61 (36.1) - 
E3, extensive colitis - - 38 (22.5) - 
unknown  34 (20.1) 
Smoking status, n (%)    
never smoker 23 (31.9) 62 (43.1) 39 (23.1) 115 (34.0) 
former smoker 22 (30.6) 34 (23.6) 69 (40.8) 96 (28.4) 
current smoker 25 (34.7) 48 (33.3) 55 (32.5) 121 (35.8) 
unknown 2 (2.8) 0 (0) 6 (3.6) 6 (1.8) 
PTH level (pmol/L), median (IQR) 2.7 (2.1–3.7) 2.7 (2.1–3.5) 2.9 (2.3–3.6) 3.0 (2.3–3.9) 
unknown, n (%) 5 (6.9) 7 (4.9) 9 (5.3) 33 (9.8) 
25(OH)D level (nmol/L), median (IQR) 59.1 (40.3–73.1) 60.4 (44.1–77.6) 54.2 (39.2–72.9) 54.9 (37.5–70.1) 
Dietary vitamin D intake (μg/day), 
median (IQR) 
3.46 (2.00–4.45) 3.03 (2.21–4.10) 3.10 (2.05–4.13) 3.09 (1.94–4.50) 
unknown, n (%) 0 (0) 0 (0) 1 (0.6) 3 (0.9) 
25(OH)D: 25-hydroxyvitamin D; CD: Crohn’s disease; IQR: interquartile range; PTH: parathyroid hormone; UC: ulcerative colitis 
 
and 4.1 years (range 0.1–15.7 years) for CD and UC, respec- 
tively. Twenty-five CD cases (34.7%) suffered from colonic 
disease and 61 UC cases (36.1%) had left-sided colitis. The 
median 25(OH)D serum level was 59.1 nmol/L (interquartile 
range [IQR] 40.3–73.1) for CD cases and 60.1 nmol/L (IQR 
44.1–77.6) for their controls. The corresponding values for UC 
cases and their controls were 54.2 nmol/L (IQR 39.2–72.9) and 
54.9 nmol/L (IQR 37.5–70.1), respectively. The distribution of 
25(OH)D concentrations of CD and UC cases and their con- 
trols is shown in Figure 1. According to predefined definitions 
of vitamin D status, 36.1% of CD cases and 34.7% of their con- 
trols had 25(OH)D levels consistent with vitamin D deficiency 
(less than 50 nmol/L), whereas 44.4% of UC cases and 43.2%. 
of their controls were vitamin D deficient. PTH concentrations 
correlated significantly with 25(OH)D concentrations, but the 
strength of the correlations was weak (P < 0.01 and r = -0.20 in 
CD cases and their controls, P < 0.01 and r = -0.22 in UC cases 
and their controls). The median daily dietary intakes of vitamin 
D were 3.46 μg (IQR 2.00–4.45) for CD cases, 3.03 μg (IQR 
2.21–4.10) for CD controls, 3.10 μg (IQR 2.05–4.13) for UC 
cases, and 3.09 μg (IQR 1.94–4.50) for UC controls. Both the 
distribution of 25(OH)D levels and dietary vitamin D intakes 
did not significantly differ between cases and controls. There 
were no significant correlations between dietary intakes of vita- 
min D and 25(OH)D concentrations (P = 0.87 and r = -0.01 in 
CD cases and their controls, P = 0.82 and r = 0.01 in UC cases 
and their controls). 
In the multivariable analyses, compared with the low- 
est quartile, there were no significant associations with the 3 
higher quartiles of 25(OH)D levels for CD (p 
trend 
= 0.34) or UC 
(p 
trend 
= 0.66) (Table 2). The analysis based on predefined cat- 
egories of  vitamin D deficiency, insufficiency, and sufficiency 
also showed no significant associations for CD (p 
trend 
= 0.58) or 
UC (p 
trend 
= 0.94) (Table 2). Similarly, when analyzing 25(OH) 
D levels as a continuous variable, serum concentrations were 
not associated with the development of IBD (OR of 0.99 [95% 
CI 0.88–1.11] per 10 nmol/L for CD and 1.01 [95% CI 0.93– 
1.11] per 10 nmol/L for UC). Additional adjustment for season 
of recruitment did not considerably change the magnitudes or 
directions of the effect sizes. Analyses based on 25(OH)D levels 
standardized by month of recruitment showed similar results 
compared with those of the nonstandardized values. 
 
  
 
 
Overall, dietary intakes of vitamin D were not associated 
with the risk of CD or UC and no significant trends across 
quartiles were observed, although individuals with a dietary 
 
FIGURE 1. Distribution of serum 25(OH)D concentrations of IBD cases and 
their controls. 
vitamin D intake in the second quartile were found to have a 
lower risk of CD and a higher risk of UC as compared to indi- 
viduals in the first and lowest quartile with an OR of 0.34 (95% 
CI 0.13–0.92) and 1.81 (95% CI 1.02–3.23) in the multivariable 
analysis of CD and UC, respectively (Table 3). 
In addition, 25(OH)D concentrations or dietary vitamin 
D intakes were not found to be associated with disease site in 
either CD or UC (data not shown). When excluding cases diag- 
nosed less than 18 months after cohort entry to minimize the 
risk of reverse causation, a slightly stronger inverse gradient 
across quartiles of 25(OH)D levels was observed in the ana- 
lysis of CD (OR for highest versus lowest quartile 0.59, 95% CI 
0.23–1.51, p 
trend 
= 0.24), but no significant associations between 
25(OH)D concentrations or dietary vitamin D intakes and CD 
or UC were observed (Supplementary Table 1). 
 
DISCUSSIO
N 
In this case-control study nested within a large European 
prospective cohort, prediagnostic 25(OH)D concentrations 
measured from serum were not associated with the development 
of CD or UC. The lack of statistically significant associations 
 
 
TABLE 2: Odds of CD and UC According to 25(OH)D Levels 
 
 Cases, 
n (%) 
Controls, 
n (%) 
Unadjusted OR 
(95% CI) 
Adjusted OR
a 
(95% CI) 
CD 
Quartile of 25(OH)D 
    
1 (≤44.0 nmol/L) 19 (26.4) 36 (25.0) 1.00 1.00 
2 (44.1–60.3 nmol/L) 21 (29.2) 36 (25.0) 1.08 (0.52–2.25) 0.94 (0.43–2.04) 
3 (60.4–77.5 nmol/L) 18 (25.0) 36 (25.0) 0.94 (0.41–2.16) 0.79 (0.33–1.89) 
4 (≥77.6 nmol/L) 
 
Predefined category of 25(OH)D 
14 (19.4) 36 (25.0) 0.74 (0.32–1.70) 
p 
trend 
= 0.41 
0.69 (0.29–1.60) 
p 
trend 
= 0.34 
Deficiency (<50.0 nmol/L) 26 (36.1) 50 (34.7) 1.00 1.00 
Insufficiency (50.0–74.9 nmol/L) 30 (41.7) 55 (38.2) 1.06 (0.52–2.18) 1.07 (0.51–2.24) 
Sufficiency (≥75.0 nmol/L) 
 
UC 
16 (22.2) 39 (27.1) 0.79 (0.36–1.71) 
p 
trend 
= 0.54 
0.80 (0.36–1.77) 
p 
trend 
= 0.58 
Quartile of 25(OH)D     
1 (≤37.5 nmol/L) 37 (21.9) 85 (25.1) 1.00 1.00 
2 (37.6–54.9 nmol/L) 48 (28.4) 85 (25.1) 1.28 (0.75–2.16) 1.28 (0.74–2.20) 
3 (55.0–70.1 nmol/L) 34 (20.1) 84 (24.9) 0.96 (0.53–1.73) 1.03 (0.56–1.89) 
4 (≥70.2 nmol/L) 
 
Predefined category of 25(OH)D 
50 (29.6) 84 (24.9) 1.37 (0.78–2.40) 
p 
trend 
= 0.38 
1.22 (0.67–2.20) 
p 
trend 
= 0.66 
Deficiency (<50.0 nmol/L) 75 (44.4) 146 (43.2) 1.00 1.00 
Insufficiency (50.0–74.9 nmol/L) 54 (32.0) 130 (38.5) 0.83 (0.53–1.28) 0.83 (0.52–1.31) 
Sufficiency (≥75.0 nmol/L) 40 (23.7) 62 (18.3) 1.26 (0.74–2.12) 
p 
trend 
= 0.57 
1.09 (0.62–1.90) 
p 
trend 
= 0.94 
25(OH)D: 25-hydroxyvitamin D; CI: confidence interval; OR: odds ratio 
aadjusted for smoking status 
 
 
 
  
 
 
 
TABLE 3: Odds of CD and UC According to Dietary Vitamin D Intake 
 
 
 
CD 
Quartile of dietary vitamin D 
Cases, 
n (%) 
Controls, 
n (%) 
Unadjusted OR 
(95% CI) 
Adjusted OR
a 
(95% CI) 
1 (≤2.21 μg/day) 24 (33.3) 36 (25.0) 1.00 1.00 
2 (2.22–3.03 μg/day) 7 (9.7) 36 (25.0) 0.32 (0.12–0.82) 0.34 (0.13–0.92) 
3 (3.04–4.10 μg/day) 18 (25.0) 36 (25.0) 0.78 (0.36–1.67) 0.94 (0.43–2.08) 
4 (≥4.11 μg/day) 23 (31.9) 36 (25.0) 1.04 (0.41–2.66) 
p 
trend 
= 0.48 
1.08 (0.41–2.85) 
p 
trend 
= 0.39 
UC 
Quartile of dietary vitamin D 
1 (≤1.94 μg/day) 30 (17.9) 83 (24.8) 1.00 1.00 
2 (1.95–3.09 μg/day) 54 (32.1) 84 (25.1) 1.82 (1.04–3.16) 1.81 (1.02–3.23) 
3 (3.10–4.50 μg/day) 50 (29.8) 84 (25.1) 1.76 (0.95–3.26) 1.83 (0.97–3.45) 
4 (≥4.51 μg/day) 34 (20.2) 84 (25.1) 1.17 (0.60–2.29) 
p 
trend 
= 0.85 
1.15 (0.58–2.29) 
p 
trend 
= 0.83 
 
 
CI: confidence interval; OR: odds ratio 
aadjusted for smoking status 
 
 
was consistent when circulating 25(OH)D levels were analyzed 
either as categorical or continuous variables. Similarly, dietary 
vitamin D intakes were not associated with the risk of incident 
CD or UC. Although based on relatively small numbers of 
cases, these findings are not supportive of a major role for vita- 
min D status in the etiology of IBD. 
Different studies have suggested vitamin D deficiency 
as a risk factor for the development of IBD.4 First, epidemio- 
logical data indicate that vitamin D deficiency is widespread, 
especially throughout western populations, and appears to rise 
in parallel with the incidence of CD and UC.1, 31, 32 Second, eco- 
logical studies have  demonstrated that the incidence of  IBD 
is greater at higher latitudes,12, 13 which could be explained by 
reduced exposure to ultraviolet B radiation from sunshine and 
consequently lower vitamin D status. However, latitude may 
not necessarily directly correlate with sunlight exposure or vita- 
min D levels33, 34 and may also reflect other factors, such as afflu- 
ence or diet.12, 35, 36 Third, vitamin D intake or status has been 
linked to an increased risk of other immunologically mediated 
diseases that may share epidemiological and pathogenic aspects 
with IBD, such as multiple sclerosis,37 rheumatoid arthritis,38 
and type 1 diabetes.39 Fourth, various genetic epidemiological 
studies have attributed susceptibility to IBD to polymorphisms 
in the VDR region, although data are not consistent.8, 9, 40, 41 
A potential link between vitamin D deficiency and the 
pathogenesis of IBD also is supported by laboratory studies. 
Most immune cells have a VDR, are able to produce the active 
form  of  vitamin  D,  1,25(OH)
2
D,  from  the  main circulating 
form, 25(OH)D, and are found to respond to this local syn- 
thesis by exerting anti-inflammatory effects.4 For example, acti- 
vation of Toll-like receptors has shown to trigger production 
 
 
of antimicrobial peptides mediated through vitamin D.42 Other 
studies have reported that vitamin D modulates proliferation 
of T-helper 1 cells and T-helper 2 cells.43 Vitamin D may also 
inhibit differentiation and maturation of dendritic cells,44 
whereas induction of immunosuppressive regulatory T cells is 
promoted.45 In different experimental mouse models, vitamin 
D or VDR deficiency has shown to result in more severe colitis, 
which may be prevented or ameliorated by administration of 
1,25(OH)
2
D.4–7 Caution in interpreting these results, however, 
is warranted since responses in mouse models do not always 
apply to human inflammatory diseases.46, 47 
In order to establish a causal relationship, the exposure 
of interest must precede the outcome. Vitamin D deficiency is 
common in both patients with CD and UC.14 However, there 
are no prospective studies examining the association between 
vitamin D status before diagnosis and the subsequent devel- 
opment of CD and UC, apart from a single large, prospective 
cohort study from the United States.15 In this investigation, 
higher predicted 25(OH)D levels were significantly associated 
with a reduced risk of incident CD. A weaker, nonsignificant 
inverse association between levels of 25(OH)D and risk of 
incident UC was reported. There was a significant inverse asso- 
ciation between dietary and supplemental vitamin D intake 
and UC and a nonsignificant inverse association with CD.15 
Participants were exclusively female nurses, which potentially 
limits the generalizability of the findings. However, the main 
weakness of this study was that the vitamin D status was based 
on predicted and not measured 25(OH)D levels. A validated 
regression model was developed to predict the plasma 25(OH) 
D level of subjects by using a set of lifestyle factors. Although 
using a predicted 25(OH)D level as a marker for vitamin D 
  
 
 
status may be useful in studies with large populations, it has 
previously been demonstrated that even a comprehensive set of 
determinants, including ultraviolet B radiation exposure, may 
account for  only around 20% to 30% of circulating 25(OH)  
D variability.16–18 Thus, the reliability of predicted circulating 
25(OH)D concentrations is modest at best. Residual confound- 
ing may be an explanation for the disparity between previous 
data and the present study. For example, the slight contribution 
of vitamin D intake to an individual’s serum vitamin status may 
cast doubt on the causality of the reported inverse association 
of dietary and supplemental vitamin D intake with IBD.15 This 
is underscored by the observation that dietary vitamin D intake 
did not correlate with 25(OH)D concentrations in the present 
study. Intake of vitamin D or a set of lifestyle determinants as a 
predictor for 25(OH)D may thus act as a proxy for other factors 
possibly associated with IBD, such as health-conscious behav- 
ior, hygiene, social status, or other yet undefined influences. It 
may also be that vitamin D deficiency does not increase the 
risk of developing CD or UC, but rather influences the course 
of disease once IBD has established. Recent studies have indi- 
cated that low 25(OH)D levels are associated with worse clin- 
ical outcomes in CD and UC,48, 49 although a low vitamin D 
status also could be a mere consequence of (active) disease. 
Finally, despite the relatively large cohort size of the present 
study, the numbers of cases may have been insufficient to detect 
modest associations. Especially for CD, there appeared to be a 
trend of an inverse association of 25(OH)D levels with CD risk. 
Nonetheless, if a small effect on risk of IBD associated with 
vitamin D status exists, the clinical relevance remains uncertain 
given the low absolute risk of CD and UC. 
The present study is the first prospective investigation to 
explore the putative role of vitamin D in the etiology of IBD 
using actual concentrations of vitamin D in blood. The 25(OH) 
D levels observed in this study are comparable to those found in 
previous epidemiological studies from general European pop- 
ulations,31 whereas relatively higher levels have been reported 
in North America.15, 50 The main strengths of this study were 
its prospective nature, which reduces the likelihood of selec- 
tion and reverse causality biases, and the direct measurement 
of serum 25(OH)D concentrations rather than a proxy marker. 
Data on the use of vitamin D supplements were not available 
for all participants and could therefore not be included in this 
study. However, measurement of 25(OH)D overcomes the 
lack of information on supplement use, since serum 25(OH)D 
incorporates vitamin D derived from endogenous production 
and from dietary intake or supplement use and can therefore 
be considered the best assessment of an individual’s vitamin D 
status.30, 51 Concentrations of vitamin D in blood are thus the 
relevant exposure measure when investigating the potential role 
of vitamin D in IBD or other diseases. Local physicians con- 
firmed all cases, and individuals who developed microscopic 
or indeterminate colitis were excluded. The odds of CD and 
UC were assessed separately and results were either matched or 
adjusted for potential confounders, such as date of enrollment 
and smoking. Lastly, data were collected from men and women 
from geographically diverse populations in Europe, increas- 
ing the generalizability of the results, together with including 
standard ranges for vitamin D and all disease sites of IBD. 
There were several limitations to this study. First, the 
assessment of 25(OH)D and dietary vitamin D intake included 
just 1 measurement. However, previous studies have shown that 
a single assessment of serum 25(OH)D has reasonable reliabil- 
ity with regard to long-term variation. Within a previous EPIC 
study, for example, it was found that serum 25(OH)D levels 
collected from 2 Dutch centers at 2 time points, several years 
apart, did not significantly change over time with a percentage 
change in mean values of 8.2% for men and 12.4% for women.22 
Furthermore, data indicate that general food patterns of adults 
remain relatively stable over time.52, 53 Second, as referred to ear- 
lier, the relatively small numbers of cases were an important 
drawback of this study, although this only appeared to hold 
for cases with CD. Although these results do not exclude the 
possibility of a small effect on IBD risk associated with vitamin 
D status, any weak association brings into question the clinical 
implications. Third, most participants developed CD or UC at 
around 55 years, whereas these disorders are commonly diag- 
nosed in the second or third decade of life. The results may 
therefore not apply to the whole IBD population, although the 
aspects of generalizability were that both men and women were 
studied and standard  determinant  of  assessments of  vitamin 
D status across different age groups was used. Moreover, the 
proportion of older patients with IBD is increasing,54 and envir- 
onmental factors appear to play a stronger role than genetics in 
the etiology of IBD in these individuals compared with younger 
patients with IBD. Fourth, results were  corrected for season 
and month of recruitment, but temporal variation of 25(OH)D 
levels may have influenced the outcomes. Finally, residual con- 
founding could not be fully excluded in this observational study. 
In conclusion, prediagnostic 25(OH)D concentrations 
measured from serum and dietary intakes of vitamin D were 
not associated with the development of CD or UC in this 
observational study in European populations. These findings 
do not suggest a major role for vitamin D status in the etiology 
of IBD. Larger studies are needed to confirm these results. 
 
SUPPLEMENTARY DATA 
Supplementary data is available at Inflammatory Bowel 
Diseases online. 
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